Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1682465rdf:typepubmed:Citationlld:pubmed
pubmed-article:1682465lifeskim:mentionsumls-concept:C0007226lld:lifeskim
pubmed-article:1682465lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:1682465lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:1682465lifeskim:mentionsumls-concept:C1533685lld:lifeskim
pubmed-article:1682465lifeskim:mentionsumls-concept:C0025859lld:lifeskim
pubmed-article:1682465lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1682465lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:1682465lifeskim:mentionsumls-concept:C0068475lld:lifeskim
pubmed-article:1682465pubmed:issue7lld:pubmed
pubmed-article:1682465pubmed:dateCreated1991-12-17lld:pubmed
pubmed-article:1682465pubmed:abstractTextThe cardiovascular effects of (+/-)-nebivolol, a potent beta 1-adrenoceptor antagonist, and its enantiomers, (+)-nebivolol (SRRR) and (-)-nebivolol (RSSS) in normotensive anaesthetized rats, have been investigated using metoprolol as a reference substance. The drugs decreased blood pressure and heart rate immediately after i.c.v. injection. These effects paralleled the beta-blocking potencies ((+)- greater than (+/-)-greater than (-)-nebivolol). Metoprolol induced a weaker hypotension than (+/-)-nebivolol, and a long-lasting reduction in stroke volume. As reported after i.v. administration, (+/-)-nebivolol and isomers by the i.c.v. route decreased peripheral vascular resistance following i.c.v. administration while metoprolol increased it. These effects are centrally mediated since cardiovascular responses to isoprenaline i.v. remained unchanged.lld:pubmed
pubmed-article:1682465pubmed:languageenglld:pubmed
pubmed-article:1682465pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1682465pubmed:citationSubsetIMlld:pubmed
pubmed-article:1682465pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1682465pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1682465pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1682465pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1682465pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1682465pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1682465pubmed:statusMEDLINElld:pubmed
pubmed-article:1682465pubmed:monthJullld:pubmed
pubmed-article:1682465pubmed:issn0022-3573lld:pubmed
pubmed-article:1682465pubmed:authorpubmed-author:CohenYYlld:pubmed
pubmed-article:1682465pubmed:authorpubmed-author:Midol-MonnetM...lld:pubmed
pubmed-article:1682465pubmed:authorpubmed-author:DavyMMlld:pubmed
pubmed-article:1682465pubmed:authorpubmed-author:HeimburgerMMlld:pubmed
pubmed-article:1682465pubmed:authorpubmed-author:BeslotFFlld:pubmed
pubmed-article:1682465pubmed:issnTypePrintlld:pubmed
pubmed-article:1682465pubmed:volume43lld:pubmed
pubmed-article:1682465pubmed:ownerNLMlld:pubmed
pubmed-article:1682465pubmed:authorsCompleteYlld:pubmed
pubmed-article:1682465pubmed:pagination504-9lld:pubmed
pubmed-article:1682465pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:1682465pubmed:meshHeadingpubmed-meshheading:1682465-...lld:pubmed
pubmed-article:1682465pubmed:meshHeadingpubmed-meshheading:1682465-...lld:pubmed
pubmed-article:1682465pubmed:meshHeadingpubmed-meshheading:1682465-...lld:pubmed
pubmed-article:1682465pubmed:meshHeadingpubmed-meshheading:1682465-...lld:pubmed
pubmed-article:1682465pubmed:meshHeadingpubmed-meshheading:1682465-...lld:pubmed
pubmed-article:1682465pubmed:meshHeadingpubmed-meshheading:1682465-...lld:pubmed
pubmed-article:1682465pubmed:meshHeadingpubmed-meshheading:1682465-...lld:pubmed
pubmed-article:1682465pubmed:meshHeadingpubmed-meshheading:1682465-...lld:pubmed
pubmed-article:1682465pubmed:meshHeadingpubmed-meshheading:1682465-...lld:pubmed
pubmed-article:1682465pubmed:meshHeadingpubmed-meshheading:1682465-...lld:pubmed
pubmed-article:1682465pubmed:meshHeadingpubmed-meshheading:1682465-...lld:pubmed
pubmed-article:1682465pubmed:meshHeadingpubmed-meshheading:1682465-...lld:pubmed
pubmed-article:1682465pubmed:meshHeadingpubmed-meshheading:1682465-...lld:pubmed
pubmed-article:1682465pubmed:year1991lld:pubmed
pubmed-article:1682465pubmed:articleTitleCardiovascular effects of intracerebroventricular injections of (+/-)-nebivolol and its enantiomers--a comparison with those of metoprolol in the rat.lld:pubmed
pubmed-article:1682465pubmed:affiliationLaboratoire de Pharmacologie, Faculté de Pharmacie, URA-CNRS 594, Châtenay-Malabry, France.lld:pubmed
pubmed-article:1682465pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1682465pubmed:publicationTypeComparative Studylld:pubmed